StimAire, a US-based injectable neuromodulation company developing medical devices for obstructive sleep apnoea (OSA), announced on Monday that it has named Arthur Rascon as its new chief operating officer (COO), effective 22 July 2024.
Rascon has more than two decades of experience in operational leadership and a proven track record of driving innovation and commercialisation in the medical device industry. He has worked as the chief executive officer at Valencia Technologies Corporation. He has worked as senior director of Manufacturing Engineering at Medtronic Diabetes, vice president of Manufacturing and Quality Engineering, and senior director of Product Engineering at Advanced Bionics.
Tarek Makansi PhD, StimAire president and chief technology officer, said, 'We are thrilled to welcome Arthur Rascon to the full-time leadership team. Arthur will move our company and product forward from a demonstrated technology to a certified medical device offering with the goal of improving the lives of those affected by obstructive sleep apnoea.'
Johnson & Johnson agrees acquisition of V-Wave
Nightingale Health gains UKCA certification and expands with new laboratory
Talphera enrols first subject in NEPHRO CRRT study
China Pharma Holdings anticipates launch of Dry Eye Disease Therapeutic Device in early 2025
SOPHiA DDM Platform achieves IVDR certification, enhancing diagnostic precision
Medtronic reports FDA approval of Simplera CGM; partners with Abbott
OncoBeta expands Rhenium-SCT (Skin Cancer Therapy) treatment services in Italy
Labcorp's PGDx elio plasma focus Dx receives US FDA De Novo marketing authorisation
Verici Dx announces completion of Thermo Fisher Scientific licensing agreement
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center